“Ultimately, I hope to help unleash the potential in students in healthcare-related programs to serve as change agents. Together we can usher in an era of unparalleled service delivery, while reducing errors, waste, and cost,” she says. “One day I will find my niche, or perhaps I shall create it.”
You are hereNews & Events
The Canadian Psychiatric Association (CPA) recognized exceptional psychiatrists, psychiatric residents and individuals for their contributions to the mental health of Canadians during their annual meeting in Vancouver on October 2.
A research study that hopes to improve the convenience and reduce the cost of a Health Canada-approved treatment for depression is underway, and the preliminary results are encouraging. Dr. Fidel Vila-Rodriguez, director of the Non-Invasive Neurostimulation Therapies (NINET) Lab at the Djavad Mowafaghian Centre for Brain Health, presented twice on his work at the Canadian Psychiatric Association Annual Meeting in Vancouver on October 1, 2015.
UBC’s investment of $1.5 million over three years in the Heart and Stroke Foundation Canadian Partnership for Stroke Recovery will accelerate the development of new therapies for people living with stroke disability.
The number of people living with multiple sclerosis (MS) in British Columbia has increased over the past 18 years, but the number of new MS cases each year has held stable, a new study has found.
Researchers hope the results of a new study will aid doctors in better supporting patients with multiple sclerosis. The study, published this week in Multiple Sclerosis Journal, tracked over 900 patients from four Canadian provinces over two years and found that during this time more than 50 percent were anxious, and over 35 percent were depressed.
New research into brain cancer suggests treatments should target the cells around a tumor to stop it from spreading.
UBC research team Christian Naus (pictured), Wun Chey Sin and John Bechberger study glioma, the most aggressive form of adult brain cancer. Glioma has a median survival rate of about 15 months and two-year survival rate of 30 per cent because it is difficult to completely remove cancer cells without compromising brain functions and chemotherapy and radiotherapy do not prevent the regrowth of remaining cancer cells.
A new test developed by UBC researchers allows physicians to measure the effects of gene silencing therapy in Huntington’s disease and will support the first human clinical trial of a drug that targets the genetic cause of the disease.
The gene silencing therapy being tested aims to reduce the levels of a toxic protein in the brain that causes Huntington’s disease.
Break out the sweatbands and the oldies – 60 minutes of good old-fashioned aerobic exercise may be more potent than any pill to reduce older adults’ risk of cognitive decline due to silent mini-strokes, according to new research by Dr. Teresa Liu-Ambrose, researcher at the Djavad Mowafaghian Centre for Brain Health.